XTI Aerospace (Nasdaq: XTIA) expects 2026 revenue to exceed $160 million — representing approximately 30% growth — as its Drone Nerds platform builds on a $110M revenue base and expands across enterprise, government, and defense markets. Management also outlined a path toward positive monthly cash flow approaching $2M by year-end 2026, highlighting operating leverage, NDAA-aligned positioning, and accelerating demand for compliant UAS solutions.

Calidi Biotherapeutics (NYSE American: CLDI) will present late-breaking data highlighting how its systemically delivered RedTail platform may enable tumor-localized expression of IL-15 superagonist and Bispecific T-Cell Engagers (BiTEs) to overcome immune suppression in solid tumors — a key limitation that has constrained BiTE efficacy beyond hematologic cancers. With IND-enabling studies underway for lead candidate CLD-401 and an IND submission targeted by year-end 2026, RedTail positions Calidi at the forefront of next-generation, tumor-targeted genetic immunotherapies.

Foremost Clean Energy (Nasdaq: FMST) is initiating a 5,000-metre follow-up drill program at its Hatchet Lake Project in Saskatchewan’s prolific Athabasca Basin, targeting expansion of its 2025 discovery that returned 0.87% U₃O₈ at the unconformity. With multiple drill-ready targets, over 5 km of untested conductive strike length, and uranium prices near US$100/lb, the fully funded winter program is designed to build on a fertile uranium system in one of the world’s premier high-grade districts.

Enlivex Therapeutics (Nasdaq: ENLV) announced that RAIN — its primary digital treasury reserve asset — has been listed on Kraken, the second-largest U.S. cryptocurrency exchange with over $2 trillion in 2025 trading volume. The added exchange access is expected to enhance liquidity and price discovery for RAIN, strengthening Enlivex’s differentiated treasury strategy while the company advances Allocetra™ in a massive osteoarthritis market affecting more than 300 million people globally.